Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
NCT06422767
Recruiting
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/14/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: Hepatitis B
Register for Updates
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
NCT06524856
Recruiting
Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health. The Lung Master is not approved by the FDA. The study has two visits approximately one month apart. In the first visit participants will take a spirometry test, particularly forced vital capacity (FVC), to measure volume change in the lungs. Participants will take the investiga... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: Biomechanics Research Building, Omaha, Nebraska
Conditions: Dyspnea, Chronic Obstructive Pulmonary Disease, Asthma
Register for Updates
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
NCT06595420
Recruiting
The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it becomes permanent. The study will compare these markers in people with CF over time and during the treatment of lung flare-ups. It will also compare the blood and urine samples obtained from people without CF. The comparison aims to better understand the impact of cystic... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +2 locations
Conditions: Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Register for Updates
The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
NCT06686914
Recruiting
The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/14/2025
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Cannabidiol Effects, Driving Performance
Register for Updates
Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
NCT06784063
Recruiting
The purpose of this study is to generate clinical data to quantify the impact of residual astigmatism on the overall visual performance during distance, intermediate, and near viewing in patients implanted with Clareon Vivity IOLs.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
04/14/2025
Locations: Grosinger, Spigelman & Grey Eye Surgeons, P.C, Bloomfield Hills, Michigan +2 locations
Conditions: Astigmatism
Register for Updates
Internet-based Talking About Risk and Adolescent Choices: Health and Emotion Regulation Options
NCT06894277
Recruiting
Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.
Gender:
ALL
Ages:
Between 12 years and 14 years
Trial Updated:
04/14/2025
Locations: Klein Buendel, Inc., Golden, Colorado
Conditions: Risky Sexual Behavior, Emotion Regulation, Adolescent Behavior
Register for Updates
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT06937970
Recruiting
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic, Phoenix, Arizona +23 locations
Conditions: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Register for Updates
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
NCT02651662
Recruiting
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, includin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of California Los Angeles Medical Center, Santa Monica, California +38 locations
Conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma
Register for Updates
The Effects of Diet and Exercise Interventions in Peripheral Artery Disease
NCT03845036
Recruiting
This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the DASH dietary program combined with a home-based exercise program, quantified by a step activity monitor, to improve exercise and vascular outcome measures in patients with PAD.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/14/2025
Locations: O'Donoghue Research Building, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Claudication, Peripheral Artery Disease
Register for Updates
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
NCT04659811
Recruiting
This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent). Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. Pembrolizumab is a humanized monoclonal antibody. An antibody... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
Register for Updates
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Recruiting
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Banner Gateway Medical Center, Gilbert, Arizona +28 locations
Conditions: Multiple Myeloma
Register for Updates
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Recruiting
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: The University of Arizona Cancer Center, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Register for Updates